Tax-related share sale by Century Therapeutics (IPSC) SVP Carr

Rhea-AI Filing Summary

Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of common stock tied to tax withholding. On June 12, 2026, he sold 1,654 shares at $2.232 per share in an open-market transaction to cover taxes from restricted stock unit vesting.

These sales were executed automatically and not at his discretion, according to the disclosure. After the transaction, Carr still directly owns 505,094 shares of Century Therapeutics common stock, indicating he retains a substantial equity position in the company.

Insider Trade Summary

Net Seller: 1,654 shares ($3,692)

Net Sell 1 txn

Insider Carr Douglas

Role SVP Finance & Operations

Sold 1,654 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,654	$2.232	$4K

Holdings After Transaction: Common Stock — 505,094 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,654 shares Sale price: $2.232 per share Shares owned after sale: 505,094 shares

3 metrics

Shares sold 1,654 shares Open-market sale on June 12, 2026

Sale price $2.232 per share Price for Century Therapeutics common stock

Shares owned after sale 505,094 shares Direct holdings of Douglas Carr following transaction

Key Terms

restricted stock units, tax withholding obligations, open-market sale

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"required to be sold ... to cover tax withholding obligations"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 12TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Finance & Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		S(1)		1,654	D	$2.232	505,094	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Century Therapeutics (IPSC) report for Douglas Carr?

Century Therapeutics reported that SVP Finance & Operations Douglas Carr sold 1,654 shares of common stock. The shares were sold to cover tax withholding obligations from restricted stock unit vesting and were executed automatically rather than at his discretion.

How many Century Therapeutics (IPSC) shares did Douglas Carr sell and at what price?

Douglas Carr sold 1,654 shares of Century Therapeutics common stock at $2.232 per share. The transaction was disclosed as an open-market sale executed to satisfy tax withholding obligations related to vesting restricted stock units.

Why were Douglas Carr’s Century Therapeutics (IPSC) shares sold in this Form 4 filing?

The filing states the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. These sales were described as automatic and not made at the personal discretion of Douglas Carr, indicating a compensation-related transaction.

How many Century Therapeutics (IPSC) shares does Douglas Carr own after this transaction?

Following the reported sale, Douglas Carr directly owns 505,094 shares of Century Therapeutics common stock. This shows that the 1,654 shares sold to cover tax obligations represent only a small portion of his overall reported holdings.

Does the Form 4 suggest discretionary selling by Douglas Carr of Century Therapeutics (IPSC) stock?

The disclosure explains that the sales were automatic to satisfy tax withholding on restricted stock unit vesting, and not at Douglas Carr’s discretion. This indicates a routine, compensation-driven transaction rather than a discretionary market-timing sale.